Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | AR | P10275 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5264662 | 1.00 | MAPT (0.50) | MAPTLMNAPOLBSMN1; SMN2SIGMAR1 | |
| SCHEMBL13987571 | 0.90 | MAPT (0.62) | MAPTLMNAPOLBSMN1; SMN2SIGMAR1 | |
| SCHEMBL9926091 | 0.88 | MAPT (0.52) | MAPTLMNAPOLBSMN1; SMN2SIGMAR1 | |
| SCHEMBL5264524 | 0.88 | MAPT (0.52) | MAPTLMNAPOLBSMN1; SMN2SIGMAR1 | |
| SCHEMBL9926068 | 0.87 | MAPT (0.45) | MAPTLMNASMN1; SMN2SIGMAR1ALDH1A1 | |
| SCHEMBL13987547 | 0.86 | AR (0.46) | MAPTLMNAPOLBSMN1; SMN2ALDH1A1 | |
| SCHEMBL5265693 | 0.86 | SMN1; SMN2 (0.52) | MAPTLMNAPOLBSMN1; SMN2ALDH1A1 | |
| SCHEMBL13987559 | 0.86 | SMN1; SMN2 (0.52) | MAPTLMNAPOLBSMN1; SMN2ALDH1A1 | |
| SCHEMBL5265503 | 0.86 | AR (0.46) | MAPTLMNAPOLBSMN1; SMN2ALDH1A1 | |
| SCHEMBL9926065 | 0.86 | MAPT (0.46) | MAPTLMNASMN1; SMN2SIGMAR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1836180-B1 | SULFONYL PYRROLIDINES, METHOD FOR PRODUCING THE SAME AND THEIR USE AS DRUGS | SANOFI SA (FR) | 2012-06-13 | — | — | EP | disclosed |
| US-7468369-B2 | Sulfonyl pyrrolidines, method for producing the same and their use as drugs | SANOFI-AVENTIS (FR) | 2008-12-23 | — | — | US | disclosed |
| US-7468369-B2 | Sulfonyl pyrrolidines, method for producing the same and their use as drugs | SANOFI-AVENTIS (FR) | 2008-12-23 | — | — | US | disclosed |
| US-20080045540-A1 | SULFONYL PYRROLIDINES, METHOD FOR PRODUCING THE SAME AND THEIR USE AS DRUGS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-02-21 | — | — | US | disclosed |
| US-20080045540-A1 | SULFONYL PYRROLIDINES, METHOD FOR PRODUCING THE SAME AND THEIR USE AS DRUGS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045540-A1 | SULFONYL PYRROLIDINES, METHOD FOR PRODUCING THE SAME AND THEIR USE AS DRUGS | SLC5A1, SLC5A2, KCNJ1 | MAPT 4225/4885LMNA 3961/4885POLB 4401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.